Luxist Web Search

Search results

1. Results From The WOW.Com Content Network

2. Amgen - Wikipedia

   en.wikipedia.org/wiki/Amgen

   Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 (8.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura ...

3. Kevin W. Sharer - Wikipedia

   en.wikipedia.org/wiki/Kevin_W._Sharer

   Kevin W. Sharer (born March 2, 1948), is an American businessman who was chairman/CEO of the biotechnology company Amgen from 2000 to 2012. He later joined the faculty of Harvard Business School teaching RC Strategy and General Management. [1] [2] [3]

4. Robert A. Bradway - Wikipedia

   en.wikipedia.org/wiki/Robert_A._Bradway

   Career. Bradway joined Morgan Stanley in New York in 1985 as a health care industry investment banker. In 1990 he moved to London, where he was a managing director with responsibility for the firm's banking department and corporate finance activities in Europe.

5. Amgen's peek at its GLP-1 drug trial results heightens ... - AOL

   www.aol.com/finance/amgens-peek-glp-1-drug...

   Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...

6. Amgen taking different path to weight loss windfall - AOL

   www.aol.com/news/amgen-taking-different-path...

   The highest tested dose in a small Phase 1 trial led to 14.5% weight loss over 12 weeks. Results from a mid-stage study are expected late this year. Both Zepbound and Wegovy are given as weekly ...

7. Amgen shares jump after teasing 'encouraging' weight loss data

   www.aol.com/news/amgen-shares-jump-teasing...

   Amgen shares trade 13.9 times their forward 12-month earnings estimates, versus a forward price-to-earnings ratio of 34.2 for Novo Nordisk and 48.49 for Eli Lilly. (Reporting by Manas Mishra in ...